Development and Validation of RP-HPLC Method for Simultaneous Estimation of Glibenclamide and Thymoquinone in Rat Plasma and Its Application to Pharmacokinetics

• Autorzy: Ahmad A. , Khan R. M. A. , Alkharfy K. M.
• Języki publikacji: EN

Abstrakty

EN

A rapid, accurate, and sensitive reverse phase high-performance liquid chromatographic method was developed and validated for the simultaneous determination and quantification of glibenclamide and thymoquinone in rat plasma in the presence of internal standard (thymol). Chromatograms were developed with methanol, acetonitrile, and buffer (50:20:30, v/v/v) solvent system on a Symmetry® C18 (5 μm, 3.9 × 150 mm) column, and pH was adjusted to 4.5 with orthophosphoric acid. Mobile phase was pumped at a flow rate of 1.5 mL min^-1 with 254 nm ultraviolet (UV) detection. Validation of the method was performed in order to demonstrate its selectivity, linearity, precision, accuracy, limits of detection, and quantification (LOD and LOQ). Standard curves were linear (r2 = 0.996 and 0.999 for glibenclamide and thymoquinone) over the concentration range 0.5–50 μg Ml^-1. The coefficient of variation (CV) of < 6% and accurate recovery of 87.54–105.19% for glibenclamide and CV of <5% and accurate recovery of 86.08–103.19% for thymoquinone were found to be in the selected concentration range of 0.5–50 μg Ml^-1. The lower limits of detection and quantitation of the method were 0.109 and 0.332 μg Ml^-1 for glibenclamide and 0.119 and 0.361 μg Ml^-1 for thymoquinone, respectively. The within and between-day coefficients of variation were less than 7%. The validated method has been successfully applied to measure the plasma concentrations in a drug interaction study of glibenclamide with thymoquinone in an animal model to illustrate the scope and application of the method.

Słowa kluczowe

EN

glibenclamide; thymoquinone; simultaneous determination; RP-HPLC; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2015
• Tom: Vol. 27, no. 3
• Strony: 435--448
• Opis fizyczny: Bibliogr. 31 poz., rys., tab.

Twórcy

autor

Ahmad A.

• Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia

autor

Khan R. M. A.

• Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia

autor

Alkharfy K. M.

• Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
• Prince Mutaib Chair for Biomarkers of Osteoporosis, King Saud University, Riyadh, 11451, Saudi Arabia
• Biomarkers Research Program, King Saud University, Riyadh, 11451, Saudi Arabia

Bibliografia

• [1] U. Panten, M. Schwanstecher, and C. Schwanstecher, Exp. Clin. Endocrinol., 104, 1 (1996)
• [2] A. Babenko, L. Paguilar-Bryan, and J. Bryan, Annu. Rev. Physiol., 60, 667, (1998)
• [3] H. Annette, LW. Cornelia, and Q. Ulrich, Br. J. Pharmacol., 136, 995, (2002)
• [4] T. Nanovskaya, I. Nekhayeva, G. Hankins, and M. Ahmed, Bio. Chem. Pharmacol., 72, 632 (2006)
• [5] D. Fückel and E. Petzinger, Eur. J. Pharmacol., 213, 393 (1992)
• [6] D.N. Sheppard and K.A. Robinson, J. Physiol., 503, 333 (1997)
• [7] M.F. Greene, N. Engl. J. Med., 343, 1178 (2000)
• [8] J.B. Chalk, M. Patterson, M.T. Smith, and M.J. Eadie, Eur. J. Clin. Pharmacol., 31, 177 (1986)
• [9] A. Ragheb, A. Attia, W.S. Eldin, F. Elbarbry, S. Gazarin, and A. Shoker, Saudi J. Kidney Dis. Transplant., 20, 741 (2009)
• [10] M.S. Butt and M.T. Sultan, Crit. Rev. Food Sci. Nutr., 50, 654 (2010)
• [11] H. Tesarova, B. Svobodova, L. Kokoska, P. Marsik, M. Pribylova, P. Landa, and J. Vadlejch, Nat. Prod. Commun., 6, 213 (2011)
• [12] O.A. Badary, M.N. Nagi, O.A. Al-Shabanah, H.A. Al-Sawaf, M.O. Al-Sohaibani, and A.M. Al-Bekairi, Can. J. Physiol. Pharmacol., 75, 1356 (1997)
• [13] P.J. Houghton, R. Zarka, B. De Las Heras, and J.R. Hoult, Planta Med., 61, 33 (1995)
• [14] A.M. Abdel-Fattah, K. Matsumoto, and H. Watanabe, Eur. J. Pharmacol., 400, 89 (2000)
• [15] H. Hosseinzadeh and S. Parvardeh, Int. J. Phytother. Phytopharmacol., 11, 56 (2004)
• [16] M. Mahfouz, R. Abdel Maguid, and M. El-Dakhakhny, Alexandria Med. J., 6, 543 (1960)
• [17] M. El-Dakhakhny, Arzneim. Forsch. Drug Res., 15, 1227 (1965)
• [18] N. Chakravarty, Ann. Allergy, 70, 237 (1993)
• [19] A. Zaoui, Y. Cherrah, M.A. Lacaille-Dubois, A. Settaf, H. Amarouch, and M. Hassar, Therapie, 5, 379 (2000)
• [20] M.H. Daba and M.S. Abdel-Rahman, Toxicol. Lett., 16, 23 (1998)
• [21] S.M. Swamy and B.K. Tan, J. Ethnopharmacol., 70, 1 (2000)
• [22] S. Enomoto, R. Asano, Y. Iwahori, T. Narui, Y. Okada, A.N. Singab, and T. Okuyama, Biol. Pharm. Bulletin, 24, 307 (2001)
• [23] K.M. Alkharfy, N.M. Al-Daghri, O.S. Al-Attas, and M.S. Alokail, Int. Immunopharmacol., 11, 250 (2011)
• [24] W.G. Goreja, Black Seed: Nature's Miracle Remedy, Amazing Herbs Press, New York, 2003, p. 54
• [25] M. Mathur, J. Gaura, R. Sharmaa, and K.R. Haldiyaa, J. Endocrinol. Metab., 1, 1 (2011)
• [26] A. Gilani, M. Jabeen, and M. Khan, Pak. J. Biol. Sci., 7, 441 (2004)
• [27] M.M. Abu Khader, Int. J. Diabetes. Dev. Countries, 32, 65 (2012)
• [28] F. Elbarbry, A. Ragheb, T. Marfleet, and A. Shoker, Phytother. Res., 26, 1726 (2012)
• [29] ICH Draft Guidelines on Validation of Analytical Procedures: Definition and Terminology, Federal Register, IFPMA, Switzerland, 1995
• [30] European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011, http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2011/08/WC500109686.pdf
• [31] K.M. Alkharfy, A. Ahmad, M.A.R. Khan, M. and Al-Asmari, J. Liq. Chromatogr. Relat. Technol., 36, 2242 (2013)